NASDAQ: CRBUCaribou Biosciences Inc Stock
$1.62+0.06 (+3.85%)
Updated Feb 4, 2026
CRBU Price
$1.62
Fair Value Price
N/A
Market Cap
$151.42M
52 Week Low
$0.66
52 Week High
$3.54
P/E
-0.95x
P/B
1.07x
P/S
23.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.30M
Earnings
-$157.13M
Gross Margin
100%
Operating Margin
-1,690.54%
Profit Margin
-1,690.4%
Debt to Equity
0.38
Operating Cash Flow
-$126M
Beta
1.85
Next Earnings
Mar 16, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CRBU Overview
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company developing genome-edited allogeneic cell therapies to treat hematologic malignancies and solid tumors. Its lead candidates are CB-010, CB-011, CB-012, and CB-020. It is collaborating with AbbVie Inc. to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRBU's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRBU
Ranked#151 of 482
Ranked#151 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $165.72 | A | |
| $6.42 | A | |
| $16.88 | A |
Be the first to know about important CRBU news, forecast changes, insider trades & much more!
CRBU News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRBU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRBU is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRBU is good value based on its book value relative to its share price (1.07x), compared to the US Biotechnology industry average (5.17x)
P/B vs Industry Valuation
CRBU is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRBU due diligence checks available for Premium users.
Valuation
CRBU fair value
Fair Value of CRBU stock based on Discounted Cash Flow (DCF)
Price
$1.62
Fair Value
-$1.96
Undervalued by
182.77%
CRBU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRBU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.95x
Industry
191.13x
Market
41.75x
CRBU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.07x
Industry
5.17x
CRBU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRBU's financial health
Profit margin
Revenue
$2.2M
Net Income
-$27.5M
Profit Margin
-1,253.3%
CRBU's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CRBU's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$195.0M
Liabilities
$53.1M
Debt to equity
0.38
CRBU's short-term assets ($155.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRBU's short-term assets ($155.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRBU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.2M
Investing
$10.9M
Financing
$277.0k
CRBU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRBU vs Biotech Stocks
Caribou Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.